Search

Displaying results 1781 - 1790 of 6198 in total
  1. Target

    Bactericidal permeability-increasing protein

    go.drugbank.com/bio_entities/BE0001112
    TargetHumans

    The cytotoxic action of BPI is limited to many species of Gram-negative bacteria; this specificity may be explained by a strong affinity of the very basic N-terminal half for the negatively charged lipopolysaccharides that are unique to ...

    Synonyms: CAP 57
  2. Target

    Calmodulin-1

    go.drugbank.com/bio_entities/BE0012563
    TargetHumans

    Calmodulin acts as part of a calcium signal transduction pathway by mediating the control of a large number of enzymes, ion channels, aquaporins and other proteins through calcium-binding (PubMed:16760425, PubMed:23893133, PubMed:2696975...

    Synonyms: CAM
  3. Drug

    Birch bark extract

    go.drugbank.com/drugs/DB16536
    ApprovedInvestigational

    [L42390] Filsuvez was subsequently approved for the same indication by the US FDA in December 2023. … [L50031] The EMA marketing authorization for Episalvan[L42370] was withdrawn by the manufacturer in 2022.

  4. Drug

    Cefepime

    go.drugbank.com/drugs/DB01413
    ApprovedInvestigational

    [A2457,A249050] Cefepime is normally used to treat severe nosocomial pneumonia and infections caused by multi-resistant microorganisms such as _Pseudomonas aeruginosa_, and is also indicated for the empirical … [A249050] The popularity of its third-generation predecessors, its clinical efficacy, and the high prevalence of multidrug-resistant bacteria might be some of the factors leading to an increase in the

  5. Drug

    Dichlorobenzyl alcohol

    go.drugbank.com/drugs/DB13269
    Approved

    [A33047] Dichlorobenzyl alcohol is considered as an active ingredient found in several marketed OTC products by Health Canada which has categorized this agent as an anatomical therapeutic chemical. … [L1113] On the other hand, dichlorobenzyl alcohol is categorized by the FDA in the inactive ingredient for approved drug products.[L2773]

  6. Drug

    Dutasteride

    go.drugbank.com/drugs/DB01126
    ApprovedInvestigational

    Dutasteride is an oral synthetic 4-azasteroid commonly marketed under the trade name Avodart. … It is a novel dual 5α-reductase inhibitor that works by blocking both isoforms of 5α-reductase enzymes in a potent, selective, and irreversible manner.

  7. Indication

    Locally Advanced Rectal Cancer (LARC)

    go.drugbank.com/conditions/DBCOND0121069
    Drugs: Capecitabine
    Synonyms: Ca rectum, CA - Cancer of rectum
  8. Drug

    Elexacaftor

    go.drugbank.com/drugs/DB15444
    ApprovedInvestigational

    [A187361] The triple combination product Trikafta<sup>TM</sup>, manufactured by Vertex Pharmaceuticals, is the first product approved for the treatment of CF in individuals who are either homo- _or_ heterozygous … [A187361] Elexacaftor, along with [VX-659], was designed to fill the need for an efficacious CF therapy for patients who are heterozygous for _F508del-CFTR_ and a gene that does not produce protein or

  9. Indication

    Breast Adenocarcinoma

    go.drugbank.com/conditions/DBCOND0029215
    Drugs: Thiotepa
    Synonyms: Ca breast, Ca breast - NOS
  10. Drug

    Sofosbuvir

    go.drugbank.com/drugs/DB08934
    ApprovedInvestigational

    With the price per pill set at $1000, a 12-week treatment can cost upwards of $84,000 per patient [A19636]. … Sofosbuvir (tradename Sovaldi) is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C